Glucotrack Seeks Shareholder Nod for $50M ELOC and Bridge Conversion, Triggering Massive Dilution

summarizeSummary

Glucotrack's preliminary proxy seeks approval for a $50M equity line and conversion of $4.45M in bridge notes, both at deep discounts that would massively dilute existing shareholders. The vote is a binary choice between survival financing and a shareholder wipeout.

check_boxKey Events · Financing and Capital Events · GCTK

• $50M ELOC with White Lion Capital

  Equity line allows Glucotrack to sell up to $50M in stock to White Lion at 97% of the lowest VWAP over 3 days (VWAP notices) or the lowest traded price (Rapid notices), with a $1M commitment fee and a $10M commitment warrant. All sales are at a discount to market, creating continuous dilution.

• Bridge Note Conversion at Steep Discount

  The $4.45M bridge notes (22% OID, 8% interest) convert at the lower of the Minimum Price or 80% of the lowest VWAP over 15 days, with a floor at 20% of the Minimum Price. At current prices, conversion could yield shares worth multiples of the current market cap, massively diluting existing holders.

• Liquidated Damages for Delayed Approval

  If shareholder approval is delayed, Glucotrack owes $50K per 30 days for the ELOC and $250K per 30 days for the bridge — payable in cash or, if approved, in stock. These penalties are severe for a company with a going-concern warning and minimal cash.

• Nasdaq Delisting Risk Intensifies

  The company already faces delisting for low stock price and equity shortfall. These deeply discounted issuances, if approved, will further depress the stock price, making compliance harder. Failure to approve triggers cash penalties that could force bankruptcy.

auto_awesomeAnalysis · GCTK · Industrial Applications And Services

Glucotrack is asking shareholders to greenlight two deeply dilutive financing deals that together could hand control to new investors. The $50 million equity line with White Lion Capital lets the company sell stock at a discount to market, while the $4.45 million bridge notes convert at a steep discount to the lowest price in 15 days — both at prices well below the current $0.45. If approved, existing holders face extreme dilution: the bridge alone could convert into shares worth many times the current float, and the ELOC adds a continuous overhang. The company is under Nasdaq delisting pressure and has a going-concern warning, so these approvals are critical to its survival — but the cost is a wipeout for current shareholders. Failure to approve triggers escalating cash penalties the company can't afford.